[ Inside the business ]

AZTA stock analysis

AZTA · Azenta, Inc.

Special industry machinery, nec. Growing 5%. Loses 28¢ on every dollar.

Watch: growth that has stopped speeding up.

The future, in 7 questions

01 What's priced in?Not available

Needs today's sales, share count and price.

02 Is the wave rising?Synthetic biology · 0.6×
'20'21'22'23'24'2536
#8 of 20 mentioning it
03 Will customers keep buying?Ten Largest Customers: 21%
Ten Largest Customers 21%Everyone else
Backlog $80M · 0.1× salesPrepaid $44MSales +5%, steady
04 Is it scarce?No
PricingBacklogPrepaidSell-outTight
05 More profit per sale?Not enough data
Before running costs: 43% → 44%
06 Can it fund itself?Pays its own way
05 yrsself-funded
Shares −7.9%/yrDebt $0
07 What could break it?2 to watch
  • Growth peaked
  • Moves strongly with the S&P 500

From SEC filings, price and Radar. Not advice.

The record

Early signals

Growth peaked.

Sales growth +1%, +12%, then +5% vs. a year ago.

What could go wrong

Red flags.

It has moved 1.6× the market. In the 2008 crisis it fell 67% while the market fell 51%. Debt is covered by cash. 1 red flag in its filings.

Speculative check

Not classified.

Not Self-funding because of: operating loss, net loss.

What they sell

45% Multiomics.

Multiomics 45% · Core Products 31% · Sample Repository Solutions 25%

Where each dollar goes

28¢ loss.

56¢ to make what it sells, 72¢ on research and overhead, nothing left over. Revenue $622M in the last 12 months.

Its market

0.3× the economy.

The government expects its industry, fabricated metal product manufacturing, to grow 0.7% a year to 2035, vs. 2.0% for the whole economy.

Market size and share

Your call.

There's no official size for its market. Enter one you trust to see its share, and slide to see what a bigger share would mean.

Life cycle

Maturity.

It earns cash, still invests, and pays back more than it borrows.

Earnings quality

Clean.

Its numbers don't resemble those of past manipulators.

Competitive advantage

0 of 10 years.

Returns beat its 10.8% cost of capital in 0 of the last 10 years. Gross margin went from 38% to 44%.

Future bets

$65M committed.

Promised to suppliers, per its latest 10-K. Plus $38M a year on research (6% of sales).

All figures from Azenta, Inc.'s SEC filings (EDGAR) unless tagged otherwise. Educational only, not investment advice.